KRAS and neoplasm: For example, in metastatic colorectal cancer, only tumours without mutations in KRAS and NRAS respond to therapy with anti-EGFR antibodies.20 It is possible that specific molecular CUP subsets might benefit from the addition of EGFR inhibition.